RAMM Pharma Statistics

Total Valuation

RAMM Pharma has a market cap or net worth of CAD 1.19 million. The enterprise value is 491,833.

Market Cap	1.19M
Enterprise Value	491,833

Important Dates

The last earnings date was Friday, June 27, 2025.

Earnings Date	Jun 27, 2025
Ex-Dividend Date	n/a

Share Statistics

RAMM Pharma has 119.39 million shares outstanding. The number of shares has decreased by -0.26% in one year.

Current Share Class	119.39M
Shares Outstanding	119.39M
Shares Change (YoY)	-0.26%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	31.43%
Owned by Institutions (%)	0.01%
Float	81.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.29
PB Ratio	0.09
P/TBV Ratio	0.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.04
EV / Sales	0.12
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.19

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.00.

Current Ratio	1.56
Quick Ratio	0.83
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-130.72

Financial Efficiency

Return on equity (ROE) is -70.13% and return on invested capital (ROIC) is -22.15%.

Return on Equity (ROE)	-70.13%
Return on Assets (ROA)	-19.70%
Return on Invested Capital (ROIC)	-22.15%
Return on Capital Employed (ROCE)	-54.86%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.19
Inventory Turnover	1.14

Taxes

In the past 12 months, RAMM Pharma has paid 12,666 in taxes.

Income Tax	12,666
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.08, so RAMM Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.08
52-Week Price Change	-33.33%
50-Day Moving Average	0.01
200-Day Moving Average	0.01
Relative Strength Index (RSI)	8.29
Average Volume (20 Days)	10,935

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RAMM Pharma had revenue of CAD 4.10 million and -13.71 million in losses. Loss per share was -0.11.

Revenue	4.10M
Gross Profit	1.52M
Operating Income	-6.99M
Pretax Income	-13.69M
Net Income	-13.71M
EBITDA	-6.27M
EBIT	-6.99M
Loss Per Share	-0.11

Full Income Statement

Balance Sheet

The company has 745,336 in cash and 43,276 in debt, giving a net cash position of 702,060 or 0.01 per share.

Cash & Cash Equivalents	745,336
Total Debt	43,276
Net Cash	702,060
Net Cash Per Share	0.01
Equity (Book Value)	12.73M
Book Value Per Share	0.11
Working Capital	1.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.50 million and capital expenditures -34,353, giving a free cash flow of -2.53 million.

Operating Cash Flow	-2.50M
Capital Expenditures	-34,353
Free Cash Flow	-2.53M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	37.01%
Operating Margin	-170.36%
Pretax Margin	-333.90%
Profit Margin	n/a
EBITDA Margin	-152.90%
EBIT Margin	-170.36%
FCF Margin	n/a

Dividends & Yields

RAMM Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.26%
Shareholder Yield	n/a
Earnings Yield	-1,148.04%
FCF Yield	-212.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RAMM Pharma has an Altman Z-Score of -6.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.68
Piotroski F-Score	3